#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neonatal asphyxia Mantle cell lymphoma refractory Immunodeficiency congenital Depression Alagille syndrome Leukoencephalopathy Osteosarcoma recurrent Infertility female Hypersomnia Cognitive disorder Haemophilia B without inhibitors Myelin oligodendrocyte glycoprotein antibody-associated disease Subdural haematoma Fusarium infection CDKL5 deficiency disorder More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Diagnostics Acquired haemophilia – Basic Information Arterial tortuosity syndrome – Diagnostics Medulloblastoma – Trials in Disease Lymphangiosarcoma – Life with Disease Encephalitis autoimmune – Treatment Glomerulonephritis membranous – Diagnostics Mucopolysaccharidosis II – Life with Disease Nodal marginal zone B-cell lymphoma Rosai-Dorfman syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Micronised Spironolactone ALFENTANIL HYDROCHLORIDE ALKYLATING AGENTS Pentixafor Enasidenib Mesilate Alxn2220 Insulin Lispro Abbv-668 Clebopride Hydrogen Maleate Fosaprepitant H2-Receptor Antagonists Daunorubicin Hydrochloride Entinostat Palivizumab OSIMERTINIB MESYLATE Selinexor Zagociguat Oxymetazoline Hydrochloride Al8326 Pyrimethamine More therapies…

    Learn about Your Condition

    Retinal vein occlusion Apathy Tachypnoea Wheezing Tardive dyskinesia Erythema migrans Lung adenocarcinoma stage III Vesicoureteric reflux Intracranial aneurysm Breast cancer stage I Transient ischaemic attack Dupuytren's contracture Kidney transplant rejection Coma Lennox-Gastaut syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone-refractory prostate cancer

  • Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Masofaniten
    • Enzalutamide
    Belgium France Spain

  • Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Metastatic malignant melanoma
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Alectinib
    • Alectinib Hydrochloride
    • Cobimetinib
    Belgium Czechia France Germany Greece Hungary +5

  • Study on the Safety and Effects of ICT01, Aldesleukin, and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Pancreatic carcinoma metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Ict01
    • Aldesleukin
    • Pembrolizumab
    France Germany

  • Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer
    Investigated Drugs:
    • Igg4 Tetravalent Bispecific Antibody-Like Protein Against Pd-1 And Ctla4
    • Dexamethasone
    • Docetaxel
    Belgium Bulgaria France Poland Spain

  • Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    France Germany Italy Spain

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Degarelix Acetate
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 … 6 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!